Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 104 entries
View as:

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05581550 Org: User:
Start: 06/29/20 End: 12/31/24 Due: 12/31/25

Pilot Study of the SPaRK (Supportive and Palliative Care Review Kit) Model of Care for Advanced Cancer Patients Who Have an Unplanned Admission to Singapore General Hospital

Phase: N/A Priority: Normal
NCT ID: NCT02559336 Org: User:
Start: 11/22/15 End: 09/30/17 Due: 09/30/18

tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)

Phase: N/A Priority: Normal
NCT ID: NCT05517135 Org: User:
Start: 11/17/22 End: 07/01/27 Due: 07/01/28

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05516628 Org: User:
Start: 02/28/23 End: 03/31/27 Due: 03/31/28

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06093061 Org: User:
Start: 07/03/24 End: 10/31/29 Due: 10/31/30

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Phase: N/A Priority: Normal
NCT ID: NCT04912765 Org: User:
Start: 04/15/21 End: 05/31/25 Due: 05/31/26

Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx

Phase: N/A Priority: Normal
NCT ID: NCT00003637 Org: User:
Start: 09/30/98 End: - Due: -

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02720926 Org: User:
Start: 09/30/11 End: 01/31/12 Due: 01/31/13

Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)

Phase: N/A Priority: Normal
NCT ID: NCT06956248 Org: User:
Start: 09/12/24 End: 03/12/27 Due: 03/12/28

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

Phase: N/A Priority: Normal
NCT ID: NCT04961632 Org: User:
Start: 12/23/20 End: 11/30/25 Due: 11/30/26

Impact of a Breast cAncer Survivorship Interprofessional Community Care Model

Phase: N/A Priority: Normal
NCT ID: NCT04660188 Org: User:
Start: 03/01/21 End: 07/20/22 Due: 07/20/23

Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00801411 Org: User:
Start: 10/31/08 End: - Due: -

Irinotecan in Treating Asian Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00731276 Org: User:
Start: 04/03/08 End: 04/30/16 Due: 04/30/17

18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study

Phase: N/A Priority: Normal
NCT ID: NCT04995185 Org: User:
Start: 06/20/17 End: 12/30/20 Due: 12/30/21

A Study Into the Effect of Seprafilm in Open Total Thyroidectomy

Phase: N/A Priority: Normal
NCT ID: NCT01865838 Org: User:
Start: 05/31/13 End: 09/30/14 Due: 09/30/15

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01029418 Org: User:
Start: 11/30/09 End: 01/31/15 Due: 01/31/16

Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02412267 Org: User:
Start: 04/30/11 End: 03/31/16 Due: 03/31/17

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Phase: N/A Priority: Normal
NCT ID: NCT03100006 Org: User:
Start: 02/22/17 End: 04/17/20 Due: 04/17/21

Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses

Phase: N/A Priority: Normal
NCT ID: NCT01540110 Org: User:
Start: 08/11/10 End: 10/20/15 Due: 10/20/16

Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

Phase: N/A Priority: Normal
NCT ID: NCT00997906 Org: User:
Start: 09/15/09 End: 12/31/23 Due: 12/31/24

Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00003576 Org: User:
Start: 01/31/97 End: 08/31/05 Due: 08/31/06

PIPAC for Peritoneal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04956068 Org: User:
Start: 05/20/21 End: 11/30/24 Due: 11/30/25

OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02368860 Org: User:
Start: 09/17/13 End: 05/21/20 Due: 05/21/21

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00690872 Org: User:
Start: 07/31/08 End: - Due: -

Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC

Phase: N/A Priority: Normal
NCT ID: NCT06294808 Org: User:
Start: 07/17/17 End: 06/30/20 Due: 06/30/21